Table 1 External validation parameters.

From: In silico exploration of novel EGFR-targeting compounds: integrative molecular modeling, docking, pharmacokinetics, and MD simulations for advancing anti-cervical cancer therapeutics

Model biasness test

SystematicErrorResult

Absent

 

R2 (residuals; serial correlation)

0.2513

 

R2 (residuals and Yobs values)

0.3870

 

R2Test(100% data)

0.9604

 

R02Test(100% data)

0.9507

Classical metrics

Q2F1(100% data)

0.9989

(for 100% data)

Q2F2(100% data)

0.9493

 

Scaled avg.Rm2(100% data)

0.8905

 

Scaled DeltaRm2(100% data)

0.0315

 

CCC(100% data)

0.9714

 

R2Test(95% data)

0.9583

 

R02Test(95% data)

0.9563

Classical metric

R02Test(95% data)

0.9567

(after removing

Q2F1(95% data)

0.9996

5% data with

Q2F2(95% data)

0.9563

high residuals)

ScaledAvgRm2(95% data)

0.9363

 

ScaledDeltaRm2(95% data)

0.0329

 

CCC(95% data)

0.9786

 

RMSEP(100% data)

0.0862

Error-based metrics

SD(100% data)

0.0665

(for 100% data)

SE(100% data)

0.0108

 

MAE(100% data)

0.0559

 

RMSEP(95% data)

0.0504

Error-based metric

SD(95% data)

0.0239

(after removing 5% data with high residuals)

SE(95% data)

0.0040

MAE(95% data)

0.0446

 

MAE + 3*SD(95% data)

0.1163

 

NCompTest

38

Number of test set compounds, range and mean (train and test)

Train range

7.8195

TrainYMean

6.7604

 

Test range

2.2201

 

TestYMean

4.1629

Response values of test set around train mean (in %)

%Y(+/-1.0)TrainMean

2.6316

%Y(+/-1.5)TrainMean

2.6316

Threshold values utilized to judge the model predictions

(0.15*TrainingSetRange)

1.1729

(0.2*TrainingSetRange)

1.5639

 

(0.25*TrainingSetRange)

1.9549

Result (MAE-based criteria applied on 95% data)

Prediction quality

Good